Vitamin D and Cardiovascular Disease Prevention

Introduction to Vitamin D and Heart Disease

Low vitamin D levels are strongly associated with increased cardiovascular events and mortality, although vitamin D supplementation has not been proven to prevent heart disease or reduce cardiovascular mortality in large interventional trials 1, 2, 3

Men with low vitamin D levels (≤15 ng/mL) have a 2.42-fold increased risk of myocardial infarction compared to those with levels ≥30 ng/mL 1, 2, 4
Moderately low vitamin D levels (22.6-29.9 ng/mL) carry a 1.60-fold increased MI risk compared to levels ≥30 ng/mL 1, 2, 4
In hypertensive patients, vitamin D levels <15 ng/mL are associated with a two-fold increase in cardiovascular events 1, 2, 4, 5

Vitamin D has multiple biologically plausible mechanisms for cardiovascular protection, including direct cardiac effects, reducing inflammation and TNF-alpha levels, controlling matrix metalloproteinases involved in vascular calcification, improving endothelial function, improving insulin secretion and sensitivity, decreasing parathyroid hormone secretion, and linking to blood pressure regulation through the renin-angiotensin-aldosterone system 1, 2, 4, 3

A meta-analysis of 8 RCTs showed vitamin D reduces blood pressure modestly but significantly in hypertensive patients (baseline BP >140/90 mmHg) 1, 2, 4, 5, 6, 3
An 8-week trial with 800 IU/day vitamin D3 plus calcium reduced systolic blood pressure more effectively than calcium alone 1, 2, 4, 3
12 months of high-dose vitamin D (83 μg/day or ~3,320 IU/day) reduced PTH, triglycerides, and TNF-alpha, but increased LDL-cholesterol 1, 2, 4, 5, 6, 3

Check vitamin D levels in patients with established cardiovascular disease who have risk factors for deficiency, such as decreased sun exposure, darker skin pigmentation, older age, inflammatory bowel disease, malabsorptive conditions, homebound or institutionalized status, or living at high latitudes 7
If vitamin D deficiency is documented (≤15 ng/mL), treat according to standard protocols for deficiency itself, not for cardiovascular benefit, with ergocalciferol 50,000 IU weekly for 8-12 weeks, followed by maintenance therapy of 800-1,000 IU daily, and monitor serum calcium and phosphorus every 3 months during treatment 8

There is a well-established inverse relationship between vitamin D levels and triglycerides, with lower vitamin D levels consistently associated with higher triglyceride levels, and vitamin D supplementation can reduce triglycerides in deficient individuals, as supported by the Autoimmunity Reviews 9

Vitamin D improves insulin secretion and insulin sensitivity, which directly affects triglyceride metabolism, according to the Autoimmunity Reviews 9
Vitamin D reduces inflammation and TNF-alpha levels, which are implicated in dyslipidemia, as noted in the Autoimmunity Reviews 9
The presence of vitamin D receptors in multiple tissues suggests direct metabolic effects on lipid handling, as mentioned in the Autoimmunity Reviews 9

An RCT in 200 healthy overweight individuals showed that 12 months of vitamin D supplementation (83 μg/day, approximately 3,320 IU/day) resulted in a significant reduction of triglycerides compared to placebo, as reported in the Autoimmunity Reviews 9

The American Heart Association guidelines note that vitamin D supplementation shows no consistent blood pressure-lowering effect in unselected populations 10, 11

The ESPEN guidelines note that loading doses up to 600,000 IU have been used safely, though follow-up monitoring is recommended 12
Vitamin D toxicity manifests through hypercalcemia rather than elevated blood pressure, and monitoring for hypercalcemia is recommended 12

The European Heart Journal and Diabetes Care suggest that hypertension should not be attributed to vitamin D supplementation without first evaluating standard causes, including beta-blockers, calcium channel blockers, NSAIDs, excessive alcohol, high sodium intake, and obesity 13, 14